Drug discovery, as a field, has evolved into a process that not only involves the scientist but also many other tangential fields such as physicians, legal experts, business individuals, etc. One portion of the drug discovery effort that is of particular challenge is that pertaining to neuroscience. This is mainly due to the complexity of the nervous system but also due to the relatively poor understanding of most psychiatric and neurological diseases. Despite this, the worldwide market for CNS disorders was estimated to be $50 billion in 2001 and is set to grow to the aging population, and due to better diagnostic procedures. However, although the process has become multi-variant over the years requiring billions of dollars to be spent for each successful launch of a drug the heart of the matter still remains to be target identification/validation and lead discovery/optimization.The Drug Discovery and Therapy World Congress 2019 to be held in Boston in September 2019, CNS (Pre-clinical Section) will try to address the major contributions toward CNS research that arises both at the industrial setting as well as the academic setting. The section will try and have a cross-section of both basic research as well as more applied (translational) research that highlights the amount of work being produced at all research sites.
It has been predicted that central nervous system (CNS) disorder will be the major medical need of this century. In spite of this recognition and the tremendous effort and money invested in CNS drug discovery, the outcome has been very limited over the last decade. Since the underlying genetic and neuronal abnormalities in most psychiatric and neurological disorders are largely unknown identifying potential pharmacological targets is particularly difficult. Furthermore, clinical evaluation of drug candidates is challenging as objective measures of symptoms of CNS diseases are frequently lacking. Therefore, adequate evaluation of the outcome, or early sign of clinical improvement of pharmacotherapeutic intervention is also complicated. Although lectures and presentations from all areas of CNS drug discovery and clinical development are welcome, a particular emphasis will be put on translational medicine. The aim will be to address some of the above listed difficulties related to the discovery of CNS medicines, while also covering hot topics, such as clinical dose selection and biomarker strategies.
Drug discovery, as a field, has evolved into a process that not only involves the scientist but also many other...
It has been predicted that central nervous system (CNS) disorder will be the major medical need of this country
“Current Alzheimer Research”, Current Impact Factor 3.289 and 5 Year Impact Factor (3.595)
For all talks and poster proposals 10th July 2019
Indiana University School of Medicine Neuroscience Research Center Indianapolis, IN 46202 USA